NEW YORK — MDNA Life Sciences said on Thursday that it has signed a Southeast Asian distribution deal for its PCR-based Mitomic Prostate Test (MPT) liquid biopsy assay with Mediwell Enterprise.
MPT is designed for the early detection of prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and patient age, based on measurement of the 3.4 kb mitochondrial DNA deletion in plasma samples.
Under the terms of the deal, Singapore-based Mediwell will exclusively distribute the test in Singapore, Malaysia, Vietnam, Thailand, Brunei, Myanmar, the Philippines, and Indonesia. Additional terms were not disclosed.
West Palm Beach, Florida-based MDNA said that it has now struck MPT distribution deals covering 35 countries, including ones with Shuwen Biotech for China and Orion Diagnostica for Germany, Denmark, Finland, Sweden, Norway, Poland, Czech Republic, Slovakia, and Hungary.
In mid-2018, MDNA exclusively licensed its technology to Laboratory Corporation of America for use in the development and commercialization of a prostate cancer test for patients with elevated PSA levels.